ID   PRKN_RAT                Reviewed;         465 AA.
AC   Q9JK66; Q8K5C3; Q8K5C4; Q8K5C5; Q8K5C6; Q8VHY6; Q9JLL1; Q9JM64;
DT   11-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   02-OCT-2024, entry version 175.
DE   RecName: Full=E3 ubiquitin-protein ligase parkin {ECO:0000305};
DE            EC=2.3.2.31 {ECO:0000269|PubMed:23661642};
DE   AltName: Full=Parkin RBR E3 ubiquitin-protein ligase {ECO:0000250|UniProtKB:O60260};
GN   Name=Prkn {ECO:0000250|UniProtKB:O60260};
GN   Synonyms=Park2 {ECO:0000312|RGD:61797};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5 AND 6).
RC   STRAIN=Sprague-Dawley;
RX   PubMed=10686358; DOI=10.1016/s0169-328x(99)00286-7;
RA   D'Agata V., Zhao W., Cavallaro S.;
RT   "Cloning and distribution of the rat parkin mRNA.";
RL   Brain Res. Mol. Brain Res. 75:345-349(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Hypothalamus;
RX   PubMed=10737637; DOI=10.1046/j.1471-4159.2000.0741773.x;
RA   Gu W.-J., Abbas N., Lagunes M.Z., Parent A., Pradier L., Bohme G.A.,
RA   Agid Y., Hirsch E.C., Raisman-Vozari R., Brice A.;
RT   "Cloning of rat parkin cDNA and distribution of parkin in rat brain.";
RL   J. Neurochem. 74:1773-1776(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=Sprague-Dawley;
RA   Hattori N., Wang M., Mizuno Y.;
RT   "The expression of parkin mRNA in developing, adult and ageing rat CNS.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RA   Soda M., Imai Y., Takahashi R.;
RT   "Molecular cloning of rat Parkin gene.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12925569; DOI=10.1093/hmg/ddg269;
RA   Huynh D.P., Scoles D.R., Nguyen D., Pulst S.M.;
RT   "The autosomal recessive juvenile Parkinson disease gene product, parkin,
RT   interacts with and ubiquitinates synaptotagmin XI.";
RL   Hum. Mol. Genet. 12:2587-2597(2003).
RN   [6]
RP   INTERACTION WITH SUMO1.
RX   PubMed=16955485; DOI=10.1002/jnr.21041;
RA   Um J.W., Chung K.C.;
RT   "Functional modulation of parkin through physical interaction with SUMO-
RT   1.";
RL   J. Neurosci. Res. 84:1543-1554(2006).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (6.5 ANGSTROMS), X-RAY CRYSTALLOGRAPHY (2.8
RP   ANGSTROMS) OF 141-465, RING-TYPE ZINC-FINGERS, CATALYTIC ACTIVITY, ACTIVE
RP   SITE, AUTOUBIQUITINATION, ACTIVITY REGULATION, AND MUTAGENESIS OF TRP-403.
RX   PubMed=23661642; DOI=10.1126/science.1237908;
RA   Trempe J.F., Sauve V., Grenier K., Seirafi M., Tang M.Y., Menade M.,
RA   Al-Abdul-Wahid S., Krett J., Wong K., Kozlov G., Nagar B., Fon E.A.,
RA   Gehring K.;
RT   "Structure of parkin reveals mechanisms for ubiquitin ligase activation.";
RL   Science 340:1451-1455(2013).
CC   -!- FUNCTION: Functions within a multiprotein E3 ubiquitin ligase complex,
CC       catalyzing the covalent attachment of ubiquitin moieties onto substrate
CC       proteins. Substrates include SYT11 and VDAC1. Other substrates are
CC       BCL2, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, SNCAIP, SEPTIN5,
CC       TOMM20, USP30, ZNF746, MIRO1 and AIMP2. Mediates monoubiquitination as
CC       well as 'Lys-6', 'Lys-11', 'Lys-48'-linked and 'Lys-63'-linked
CC       polyubiquitination of substrates depending on the context. Participates
CC       in the removal and/or detoxification of abnormally folded or damaged
CC       protein by mediating 'Lys-63'-linked polyubiquitination of misfolded
CC       proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded
CC       proteins are then recognized by HDAC6, leading to their recruitment to
CC       aggresomes, followed by degradation. Mediates 'Lys-63'-linked
CC       polyubiquitination of a 22 kDa O-linked glycosylated isoform of SNCAIP,
CC       possibly playing a role in Lewy-body formation. Mediates
CC       monoubiquitination of BCL2, thereby acting as a positive regulator of
CC       autophagy. Protects against mitochondrial dysfunction during cellular
CC       stress, by acting downstream of PINK1 to coordinate mitochondrial
CC       quality control mechanisms that remove and replace dysfunctional
CC       mitochondrial components. Depending on the severity of mitochondrial
CC       damage and/or dysfunction, activity ranges from preventing apoptosis
CC       and stimulating mitochondrial biogenesis to regulating mitochondrial
CC       dynamics and eliminating severely damaged mitochondria via mitophagy.
CC       Activation and recruitment onto the outer membrane of
CC       damaged/dysfunctional mitochondria (OMM) requires PINK1-mediated
CC       phosphorylation of both PRKN and ubiquitin. After mitochondrial damage,
CC       functions with PINK1 to mediate the decision between mitophagy or
CC       preventing apoptosis by inducing either the poly- or monoubiquitination
CC       of VDAC1, respectively; polyubiquitination of VDAC1 promotes mitophagy,
CC       while monoubiquitination of VDAC1 decreases mitochondrial calcium
CC       influx which ultimately inhibits apoptosis. When cellular stress
CC       results in irreversible mitochondrial damage, promotes the autophagic
CC       degradation of dysfunctional depolarized mitochondria (mitophagy) by
CC       promoting the ubiquitination of mitochondrial proteins such as TOMM20,
CC       RHOT1/MIRO1, MFN1 and USP30. Preferentially assembles 'Lys-6'-, 'Lys-
CC       11'- and 'Lys-63'-linked polyubiquitin chains, leading to mitophagy.
CC       The PINK1-PRKN pathway also promotes fission of damaged mitochondria by
CC       PINK1-mediated phosphorylation which promotes the PRKN-dependent
CC       degradation of mitochondrial proteins involved in fission such as MFN2.
CC       This prevents the refusion of unhealthy mitochondria with the
CC       mitochondrial network or initiates mitochondrial fragmentation
CC       facilitating their later engulfment by autophagosomes. Regulates
CC       motility of damaged mitochondria via the ubiquitination and subsequent
CC       degradation of MIRO1 and MIRO2; in motor neurons, this likely inhibits
CC       mitochondrial intracellular anterograde transport along the axons which
CC       probably increases the chance of the mitochondria undergoing mitophagy
CC       in the soma. Involved in mitochondrial biogenesis via the 'Lys-48'-
CC       linked polyubiquitination of transcriptional repressor ZNF746/PARIS
CC       which leads to its subsequent proteasomal degradation and allows
CC       activation of the transcription factor PPARGC1A. Limits the production
CC       of reactive oxygen species (ROS). Regulates cyclin-E during neuronal
CC       apoptosis. In collaboration with CHPF isoform 2, may enhance cell
CC       viability and protect cells from oxidative stress. Independently of its
CC       ubiquitin ligase activity, protects from apoptosis by the
CC       transcriptional repression of p53/TP53. May protect neurons against
CC       alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation,
CC       and kainate-induced excitotoxicity. May play a role in controlling
CC       neurotransmitter trafficking at the presynaptic terminal and in
CC       calcium-dependent exocytosis. May represent a tumor suppressor gene.
CC       {ECO:0000250|UniProtKB:O60260}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[E2 ubiquitin-conjugating enzyme]-S-ubiquitinyl-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + [acceptor protein]-N(6)-ubiquitinyl-L-lysine.;
CC         EC=2.3.2.31; Evidence={ECO:0000269|PubMed:23661642};
CC   -!- ACTIVITY REGULATION: In the autoinhibited state the side chain of Phe-
CC       463 inserts into a hydrophobic groove in RING-0, occluding the
CC       ubiquitin acceptor site Cys-431, whereas the REP repressor element
CC       binds RING-1 and blocks its E2-binding site. Activation of PRKN
CC       requires 2 steps: (1) phosphorylation at Ser-65 by PINK1 and (2)
CC       binding to phosphorylated ubiquitin, leading to unlock repression of
CC       the catalytic Cys-431 by the RING-0 region via an allosteric mechanism
CC       and converting PRKN to its fully-active form. According to another
CC       report, phosphorylation at Ser-65 by PINK1 is not essential for
CC       activation and only binding to phosphorylated ubiquitin is essential to
CC       unlock repression. In addition, ISG15 conjugation positively regulates
CC       its ubiquitin E3 ligase activity by suppressing the intramolecular
CC       interaction that maintains its autoinhibited conformation.
CC       {ECO:0000250|UniProtKB:O60260, ECO:0000269|PubMed:23661642}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Forms an E3 ubiquitin ligase complex with UBE2L3 or UBE2L6.
CC       Mediates 'Lys-63'-linked polyubiquitination by associating with UBE2V1.
CC       Part of a SCF-like complex, consisting of PRKN, CUL1 and FBXW7.
CC       Interacts with SNCAIP. Binds to the C2A and C2B domains of SYT11.
CC       Interacts and regulates the turnover of SEPTIN5. Part of a complex,
CC       including STUB1, HSP70 and GPR37. The amount of STUB1 in the complex
CC       increases during ER stress. STUB1 promotes the dissociation of HSP70
CC       from PRKN and GPR37, thus facilitating PRKN-mediated GPR37
CC       ubiquitination. HSP70 transiently associates with unfolded GPR37 and
CC       inhibits the E3 activity of PRKN, whereas, STUB1 enhances the E3
CC       activity of PRKN through promotion of dissociation of HSP70 from PRKN-
CC       GPR37 complexes. Interacts with PSMD4 and PACRG. Interacts with LRRK2.
CC       Interacts with RANBP2. Interacts with SUMO1 but not SUMO2, which
CC       promotes nuclear localization and autoubiquitination. Interacts (via
CC       first RING-type domain) with AIMP2 (via N-terminus). Interacts with
CC       PSMA7 and RNF41. Interacts with PINK1. Forms a complex with PINK1 and
CC       PARK7. Interacts with CHPF, the interaction with isoform 2 may
CC       facilitate PRKN transport into the mitochondria. Interacts with MFN2
CC       (phosphorylated), promotes PRKN localization in dysfunctional
CC       depolarized mitochondria. Interacts with FBXO7; this promotes
CC       translocation to dysfunctional depolarized mitochondria. Interacts with
CC       ZNF746. Interacts with heat shock protein 70 family members, including
CC       HSPA1L, HSPA1A and HSPA8; interaction HSPA1L promotes translocation to
CC       damaged mitochondria. Interacts with BAG4 and, to a lesser extent,
CC       BAG5; interaction with BAG4 inhibits translocation to damaged
CC       mitochondria. Forms a complex with PRKN and PARK7. Interacts with
CC       AMBRA1 (By similarity). {ECO:0000250|UniProtKB:O60260,
CC       ECO:0000250|UniProtKB:Q9WVS6}.
CC   -!- INTERACTION:
CC       Q9JK66; D4A054: Ranbp2; NbExp=2; IntAct=EBI-973793, EBI-973937;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:12925569}.
CC       Nucleus {ECO:0000250|UniProtKB:O60260}. Endoplasmic reticulum
CC       {ECO:0000250|UniProtKB:O60260}. Mitochondrion
CC       {ECO:0000250|UniProtKB:O60260}. Mitochondrion outer membrane
CC       {ECO:0000250|UniProtKB:Q9WVS6}. Cell projection, neuron projection
CC       {ECO:0000269|PubMed:12925569}. Postsynaptic density
CC       {ECO:0000250|UniProtKB:Q9WVS6}. Presynapse
CC       {ECO:0000250|UniProtKB:Q9WVS6}. Note=Mainly localizes in the cytosol.
CC       Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in
CC       brainstem Lewy bodies. Translocates to dysfunctional mitochondria that
CC       have lost the mitochondrial membrane potential; recruitment to
CC       mitochondria is PINK1-dependent. Mitochondrial localization also
CC       gradually increases with cellular growth.
CC       {ECO:0000250|UniProtKB:O60260}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1;
CC         IsoId=Q9JK66-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9JK66-2; Sequence=VSP_011722, VSP_011723;
CC       Name=3;
CC         IsoId=Q9JK66-3; Sequence=VSP_011717;
CC       Name=4;
CC         IsoId=Q9JK66-4; Sequence=VSP_011718;
CC       Name=5;
CC         IsoId=Q9JK66-5; Sequence=VSP_011719;
CC       Name=6;
CC         IsoId=Q9JK66-6; Sequence=VSP_011717, VSP_011720, VSP_011721;
CC   -!- TISSUE SPECIFICITY: Largely confined to neuronal elements, including
CC       fibers and neuropil. Highly expressed at the forebrain level, in
CC       pyramidal cells of layer V, in various cortical regions and cerebellum.
CC       Expressed in the nucleus of diagonal band of Broca, nucleus basalis,
CC       bed nucleus of the stria terminalis, and olfactory tubercle. Moderate
CC       expression is seen in most neurons of the subthalamic nucleus, heart,
CC       skeletal muscle and testis. Moderate expression was found in frontal
CC       cortex, parietal cortex, cerebellum, heart, skeletal muscle and testis.
CC       {ECO:0000269|PubMed:10737637}.
CC   -!- DOMAIN: The ubiquitin-like domain binds the PSMD4 subunit of 26S
CC       proteasomes. {ECO:0000250|UniProtKB:O60260}.
CC   -!- DOMAIN: The RING-type 1 zinc finger domain is required to repress
CC       p53/TP53 transcription. {ECO:0000250|UniProtKB:O60260}.
CC   -!- DOMAIN: Members of the RBR family are atypical E3 ligases. They
CC       interact with the E2 conjugating enzyme UBE2L3 and function like HECT-
CC       type E3 enzymes: they bind E2s via the first RING domain, but require
CC       an obligate trans-thiolation step during the ubiquitin transfer,
CC       requiring a conserved cysteine residue in the second RING domain.
CC       {ECO:0000250|UniProtKB:O60260}.
CC   -!- PTM: Auto-ubiquitinates in an E2-dependent manner leading to its own
CC       degradation (PubMed:23661642). Also polyubiquitinated by RNF41 for
CC       proteasomal degradation (By similarity). {ECO:0000250|UniProtKB:O60260,
CC       ECO:0000269|PubMed:23661642}.
CC   -!- PTM: S-nitrosylated. {ECO:0000250|UniProtKB:O60260}.
CC   -!- PTM: Phosphorylated. Activation requires phosphorylation at Ser-65 by
CC       PINK1 and binding to PINK1 phosphorylated ubiquitin. Phosphorylation at
CC       Thr-175 by PINK1 and at Thr-217 is important for mitochondrial
CC       localization. {ECO:0000250|UniProtKB:O60260}.
CC   -!- SIMILARITY: Belongs to the RBR family. Parkin subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF343574; AAL73348.1; -; mRNA.
DR   EMBL; AF381277; AAM21452.1; -; mRNA.
DR   EMBL; AF381278; AAM21453.1; -; mRNA.
DR   EMBL; AF381279; AAM21454.1; -; mRNA.
DR   EMBL; AF381280; AAM21455.1; -; mRNA.
DR   EMBL; AF381281; AAM21456.1; -; mRNA.
DR   EMBL; AF168004; AAF34874.1; -; mRNA.
DR   EMBL; AF210434; AAG37013.1; -; mRNA.
DR   EMBL; AF257234; AAF68666.1; -; mRNA.
DR   EMBL; AB039878; BAA92431.1; -; mRNA.
DR   RefSeq; NP_064478.1; NM_020093.1.
DR   PDB; 2KNB; NMR; -; A=1-76.
DR   PDB; 4K7D; X-ray; 2.80 A; A/B/C=141-465.
DR   PDB; 4K95; X-ray; 6.50 A; A/B/C/D/E/F/G/H/I/J/K/L=1-465.
DR   PDB; 4ZYN; X-ray; 2.54 A; A/B=1-465.
DR   PDB; 7US1; X-ray; 2.48 A; A=145-379.
DR   PDBsum; 2KNB; -.
DR   PDBsum; 4K7D; -.
DR   PDBsum; 4K95; -.
DR   PDBsum; 4ZYN; -.
DR   PDBsum; 7US1; -.
DR   AlphaFoldDB; Q9JK66; -.
DR   BMRB; Q9JK66; -.
DR   SMR; Q9JK66; -.
DR   BioGRID; 248590; 31.
DR   DIP; DIP-37656N; -.
DR   IntAct; Q9JK66; 1.
DR   MINT; Q9JK66; -.
DR   STRING; 10116.ENSRNOP00000075137; -.
DR   GlyGen; Q9JK66; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9JK66; -.
DR   PhosphoSitePlus; Q9JK66; -.
DR   PaxDb; 10116-ENSRNOP00000040511; -.
DR   Ensembl; ENSRNOT00000096213.1; ENSRNOP00000077507.1; ENSRNOG00000055547.2. [Q9JK66-1]
DR   Ensembl; ENSRNOT00000107769.1; ENSRNOP00000088932.1; ENSRNOG00000055547.2. [Q9JK66-3]
DR   GeneID; 56816; -.
DR   KEGG; rno:56816; -.
DR   AGR; RGD:61797; -.
DR   CTD; 5071; -.
DR   RGD; 61797; Prkn.
DR   eggNOG; KOG0006; Eukaryota.
DR   GeneTree; ENSGT00390000011034; -.
DR   InParanoid; Q9JK66; -.
DR   OrthoDB; 3084186at2759; -.
DR   PhylomeDB; Q9JK66; -.
DR   Reactome; R-RNO-5205685; PINK1-PRKN Mediated Mitophagy.
DR   Reactome; R-RNO-5675482; Regulation of necroptotic cell death.
DR   Reactome; R-RNO-5689877; Josephin domain DUBs.
DR   Reactome; R-RNO-9646399; Aggrephagy.
DR   Reactome; R-RNO-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   EvolutionaryTrace; Q9JK66; -.
DR   PRO; PR:Q9JK66; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   GO; GO:0016235; C:aggresome; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0098691; C:dopaminergic synapse; ISO:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0005794; C:Golgi apparatus; ISO:RGD.
DR   GO; GO:0000139; C:Golgi membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0097708; C:intracellular vesicle; IDA:RGD.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0099073; C:mitochondrion-derived vesicle; ISO:RGD.
DR   GO; GO:0043005; C:neuron projection; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:1990452; C:Parkin-FBXW7-Cul1 ubiquitin ligase complex; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0098794; C:postsynapse; IDA:SynGO.
DR   GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell.
DR   GO; GO:0098793; C:presynapse; IDA:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0045202; C:synapse; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0008021; C:synaptic vesicle; IDA:RGD.
DR   GO; GO:0030672; C:synaptic vesicle membrane; IDA:RGD.
DR   GO; GO:0043195; C:terminal bouton; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000151; C:ubiquitin ligase complex; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0003779; F:actin binding; ISO:RGD.
DR   GO; GO:0008013; F:beta-catenin binding; ISO:RGD.
DR   GO; GO:0097602; F:cullin family protein binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:1990444; F:F-box domain binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0031072; F:heat shock protein binding; ISO:RGD.
DR   GO; GO:0042826; F:histone deacetylase binding; ISO:RGD.
DR   GO; GO:0030544; F:Hsp70 protein binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0019900; F:kinase binding; ISO:RGD.
DR   GO; GO:0030165; F:PDZ domain binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043274; F:phospholipase binding; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0051087; F:protein-folding chaperone binding; ISO:RGD.
DR   GO; GO:0003714; F:transcription corepressor activity; ISO:RGD.
DR   GO; GO:0015631; F:tubulin binding; ISO:RGD.
DR   GO; GO:0043130; F:ubiquitin binding; ISS:UniProtKB.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; ISS:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:RGD.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; ISS:UniProtKB.
DR   GO; GO:1990381; F:ubiquitin-specific protease binding; ISO:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0008344; P:adult locomotory behavior; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0070842; P:aggresome assembly; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0000422; P:autophagy of mitochondrion; ISS:UniProtKB.
DR   GO; GO:1904881; P:cellular response to hydrogen sulfide; IDA:RGD.
DR   GO; GO:1905232; P:cellular response to L-glutamate; IDA:RGD.
DR   GO; GO:1904845; P:cellular response to L-glutamine; IEP:RGD.
DR   GO; GO:0071287; P:cellular response to manganese ion; IEP:RGD.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0097237; P:cellular response to toxic substance; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0042417; P:dopamine metabolic process; ISO:RGD.
DR   GO; GO:0051583; P:dopamine uptake involved in synaptic transmission; ISO:RGD.
DR   GO; GO:0010994; P:free ubiquitin chain polymerization; ISO:RGD.
DR   GO; GO:0007612; P:learning; ISO:RGD.
DR   GO; GO:0007626; P:locomotory behavior; ISO:RGD.
DR   GO; GO:0000266; P:mitochondrial fission; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IMP:RGD.
DR   GO; GO:0051646; P:mitochondrion localization; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007005; P:mitochondrion organization; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0099074; P:mitochondrion to lysosome vesicle-mediated transport; ISO:RGD.
DR   GO; GO:0000423; P:mitophagy; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0044828; P:negative regulation by host of viral genome replication; ISO:RGD.
DR   GO; GO:0032232; P:negative regulation of actin filament bundle assembly; ISO:RGD.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; ISO:RGD.
DR   GO; GO:1902236; P:negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1903382; P:negative regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; IMP:RGD.
DR   GO; GO:1903542; P:negative regulation of exosomal secretion; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0033132; P:negative regulation of glucokinase activity; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1905366; P:negative regulation of intralumenal vesicle formation; ISO:RGD.
DR   GO; GO:1902254; P:negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator; ISO:RGD.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0090258; P:negative regulation of mitochondrial fission; IMP:RGD.
DR   GO; GO:0010637; P:negative regulation of mitochondrial fusion; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:RGD.
DR   GO; GO:1903377; P:negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1903427; P:negative regulation of reactive oxygen species biosynthetic process; IMP:RGD.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1904049; P:negative regulation of spontaneous neurotransmitter secretion; ISO:RGD.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IMP:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0070050; P:neuron cellular homeostasis; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0042415; P:norepinephrine metabolic process; ISO:RGD.
DR   GO; GO:0061734; P:parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization; ISO:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:2001171; P:positive regulation of ATP biosynthetic process; IMP:RGD.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1903861; P:positive regulation of dendrite extension; ISO:RGD.
DR   GO; GO:0043388; P:positive regulation of DNA binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; IMP:RGD.
DR   GO; GO:0090141; P:positive regulation of mitochondrial fission; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0010636; P:positive regulation of mitochondrial fusion; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0010918; P:positive regulation of mitochondrial membrane potential; IMP:RGD.
DR   GO; GO:1901526; P:positive regulation of mitophagy; IMP:RGD.
DR   GO; GO:0098779; P:positive regulation of mitophagy in response to mitochondrial depolarization; ISO:RGD.
DR   GO; GO:0051582; P:positive regulation of neurotransmitter uptake; ISO:RGD.
DR   GO; GO:1901800; P:positive regulation of proteasomal protein catabolic process; ISO:RGD.
DR   GO; GO:1902530; P:positive regulation of protein linear polyubiquitination; ISO:RGD.
DR   GO; GO:1905477; P:positive regulation of protein localization to membrane; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1903265; P:positive regulation of tumor necrosis factor-mediated signaling pathway; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0010498; P:proteasomal protein catabolic process; ISO:RGD.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0051865; P:protein autoubiquitination; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0030163; P:protein catabolic process; ISO:RGD.
DR   GO; GO:0031648; P:protein destabilization; ISS:UniProtKB.
DR   GO; GO:0070979; P:protein K11-linked ubiquitination; ISS:UniProtKB.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; ISO:RGD.
DR   GO; GO:0085020; P:protein K6-linked ubiquitination; ISS:UniProtKB.
DR   GO; GO:0070534; P:protein K63-linked ubiquitination; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0070585; P:protein localization to mitochondrion; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006513; P:protein monoubiquitination; ISS:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0050821; P:protein stabilization; ISO:RGD.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0010506; P:regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:1900407; P:regulation of cellular response to oxidative stress; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0042053; P:regulation of dopamine metabolic process; ISO:RGD.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; ISO:RGD.
DR   GO; GO:0010821; P:regulation of mitochondrion organization; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0046928; P:regulation of neurotransmitter secretion; ISO:RGD.
DR   GO; GO:0099072; P:regulation of postsynaptic membrane neurotransmitter receptor levels; IDA:SynGO.
DR   GO; GO:0031647; P:regulation of protein stability; ISO:RGD.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; ISO:RGD.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; ISO:RGD.
DR   GO; GO:1900242; P:regulation of synaptic vesicle endocytosis; ISO:RGD.
DR   GO; GO:0140251; P:regulation protein catabolic process at presynapse; ISO:RGD.
DR   GO; GO:0051412; P:response to corticosterone; IEP:RGD.
DR   GO; GO:1904643; P:response to curcumin; IEP:RGD.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IEP:RGD.
DR   GO; GO:0014850; P:response to muscle activity; IEP:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0006986; P:response to unfolded protein; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0001964; P:startle response; ISO:RGD.
DR   GO; GO:0001963; P:synaptic transmission, dopaminergic; ISO:RGD.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; ISO:RGD.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; ISS:ParkinsonsUK-UCL.
DR   CDD; cd20340; BRcat_RBR_parkin; 1.
DR   CDD; cd20357; Rcat_RBR_parkin; 1.
DR   CDD; cd16627; RING-HC_RBR_parkin; 1.
DR   CDD; cd21382; RING0_parkin; 1.
DR   CDD; cd01798; Ubl_parkin; 1.
DR   DisProt; DP01850; -.
DR   Gene3D; 1.20.120.1750; -; 1.
DR   Gene3D; 2.20.25.20; -; 1.
DR   InterPro; IPR047534; BRcat_RBR_parkin.
DR   InterPro; IPR031127; E3_UB_ligase_RBR.
DR   InterPro; IPR002867; IBR_dom.
DR   InterPro; IPR003977; Parkin.
DR   InterPro; IPR041565; Parkin_Znf-RING.
DR   InterPro; IPR047536; Rcat_RBR_parkin.
DR   InterPro; IPR047535; RING-HC_RBR_parkin.
DR   InterPro; IPR044066; TRIAD_supradom.
DR   InterPro; IPR000626; Ubiquitin-like_dom.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   InterPro; IPR041170; Znf-RING_14.
DR   PANTHER; PTHR11685:SF471; E3 UBIQUITIN-PROTEIN LIGASE PARKIN; 1.
DR   PANTHER; PTHR11685; RBR FAMILY RING FINGER AND IBR DOMAIN-CONTAINING; 1.
DR   Pfam; PF22605; IBR_2; 1.
DR   Pfam; PF00240; ubiquitin; 1.
DR   Pfam; PF17976; zf-RING_12; 1.
DR   Pfam; PF17978; zf-RING_14; 1.
DR   PIRSF; PIRSF037880; Parkin; 1.
DR   PRINTS; PR01475; PARKIN.
DR   SMART; SM00647; IBR; 2.
DR   SMART; SM00213; UBQ; 1.
DR   SUPFAM; SSF57850; RING/U-box; 2.
DR   SUPFAM; SSF54236; Ubiquitin-like; 1.
DR   PROSITE; PS51873; TRIAD; 1.
DR   PROSITE; PS50053; UBIQUITIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autophagy; Cell projection; Cytoplasm;
KW   Endoplasmic reticulum; Isopeptide bond; Membrane; Metal-binding;
KW   Mitochondrion; Mitochondrion outer membrane; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Synapse; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..465
FT                   /note="E3 ubiquitin-protein ligase parkin"
FT                   /id="PRO_0000058578"
FT   DOMAIN          1..76
FT                   /note="Ubiquitin-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00214"
FT   ZN_FING         141..225
FT                   /note="RING-type 0; atypical"
FT   ZN_FING         238..293
FT                   /note="RING-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   ZN_FING         313..377
FT                   /note="IBR-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   ZN_FING         418..449
FT                   /note="RING-type 2; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   REGION          71..96
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          77..237
FT                   /note="Necessary for PINK1-dependent localization to
FT                   mitochondria"
FT                   /evidence="ECO:0000250|UniProtKB:O60260"
FT   REGION          204..238
FT                   /note="SYT11 binding 1"
FT                   /evidence="ECO:0000250|UniProtKB:O60260"
FT   REGION          234..465
FT                   /note="TRIAD supradomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   REGION          257..293
FT                   /note="SYT11 binding 2"
FT                   /evidence="ECO:0000250|UniProtKB:O60260"
FT   REGION          378..410
FT                   /note="REP"
FT                   /evidence="ECO:0000269|PubMed:23661642"
FT   ACT_SITE        431
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221,
FT                   ECO:0000269|PubMed:23661642"
FT   BINDING         238
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         241
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         253
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         257
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         260
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         263
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         289
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         293
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         332
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         337
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         352
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         360
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         365
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         368
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         373
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         377
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         418
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         421
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         436
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         441
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         446
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         449
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         457
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         461
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   MOD_RES         65
FT                   /note="Phosphoserine; by PINK1"
FT                   /evidence="ECO:0000250|UniProtKB:O60260"
FT   MOD_RES         80
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WVS6"
FT   MOD_RES         175
FT                   /note="Phosphothreonine; by PINK1"
FT                   /evidence="ECO:0000250|UniProtKB:O60260"
FT   MOD_RES         217
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O60260"
FT   CROSSLNK        349
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ISG15)"
FT                   /evidence="ECO:0000250|UniProtKB:O60260"
FT   CROSSLNK        369
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ISG15)"
FT                   /evidence="ECO:0000250|UniProtKB:O60260"
FT   VAR_SEQ         1..191
FT                   /note="Missing (in isoform 3 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:10686358"
FT                   /id="VSP_011717"
FT   VAR_SEQ         57
FT                   /note="Q -> QHPQDGFCHKSHLAVHNLSQQDVTQ (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10686358"
FT                   /id="VSP_011718"
FT   VAR_SEQ         179..206
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:10686358"
FT                   /id="VSP_011719"
FT   VAR_SEQ         390..394
FT                   /note="AYRVD -> EDVCT (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:10686358"
FT                   /id="VSP_011720"
FT   VAR_SEQ         395..465
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:10686358"
FT                   /id="VSP_011721"
FT   VAR_SEQ         429..446
FT                   /note="GGCMHMKCPQPQCKLEWC -> ERMHVQYTMCIPGAHGGY (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:10686358"
FT                   /id="VSP_011722"
FT   VAR_SEQ         447..465
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10686358"
FT                   /id="VSP_011723"
FT   MUTAGEN         403
FT                   /note="W->A: Increased autoubiquitination."
FT                   /evidence="ECO:0000269|PubMed:23661642"
FT   CONFLICT        24
FT                   /note="F -> C (in Ref. 1; AAF34874)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        138
FT                   /note="E -> A (in Ref. 3; BAA92431)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        348
FT                   /note="K -> R (in Ref. 3; BAA92431)"
FT                   /evidence="ECO:0000305"
FT   STRAND          2..11
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   STRAND          13..16
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   HELIX           23..34
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   HELIX           38..40
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   STRAND          41..45
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   STRAND          48..50
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   HELIX           56..59
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   STRAND          65..71
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   STRAND          147..150
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   TURN            151..154
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   STRAND          156..166
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   TURN            167..169
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   STRAND          174..178
FT                   /evidence="ECO:0007829|PDB:4K7D"
FT   HELIX           183..187
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   STRAND          193..196
FT                   /evidence="ECO:0007829|PDB:4K7D"
FT   STRAND          205..215
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   STRAND          223..225
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   TURN            239..241
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   STRAND          246..250
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   STRAND          253..255
FT                   /evidence="ECO:0007829|PDB:4K7D"
FT   STRAND          258..260
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   HELIX           261..273
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   STRAND          278..280
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   TURN            281..283
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   STRAND          284..286
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   HELIX           301..307
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   HELIX           309..326
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   TURN            335..337
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   STRAND          349..351
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   TURN            356..358
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   STRAND          363..365
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   TURN            366..368
FT                   /evidence="ECO:0007829|PDB:7US1"
FT   HELIX           395..400
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   STRAND          401..403
FT                   /evidence="ECO:0007829|PDB:4K7D"
FT   STRAND          415..417
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   TURN            419..421
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   STRAND          424..426
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   STRAND          429..431
FT                   /evidence="ECO:0007829|PDB:4K7D"
FT   STRAND          433..435
FT                   /evidence="ECO:0007829|PDB:4K7D"
FT   TURN            439..441
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   STRAND          444..446
FT                   /evidence="ECO:0007829|PDB:4K7D"
FT   TURN            447..449
FT                   /evidence="ECO:0007829|PDB:4ZYN"
FT   HELIX           455..461
FT                   /evidence="ECO:0007829|PDB:4ZYN"
SQ   SEQUENCE   465 AA;  51709 MW;  E13CF170AD6D042B CRC64;
     MIVFVRFNSS YGFPVEVDSD TSIFQLKEVV AKRQGVPADQ LRVIFAGKEL QNHLTVQNCD
     LEQQSIVHIV QRPQRKSHET NASGGDKPQS TPEGSIWEPR SLTRVDLSSH ILPADSVGLA
     VILDTDSKSD SEAARGPEAK PTYHSFFVYC KGPCHKVQPG KLRVQCGTCR QATLTLAQGP
     SCWDDVLIPN RMSGECQSPD CPGTRAEFFF KCGAHPTSDK DTSVALNLIT NNSRSIPCIA
     CTDVRNPVLV FQCNHRHVIC LDCFHLYCVT RLNDRQFVHD AQLGYSLPCV AGCPNSLIKE
     LHHFRILGEE QYNRYQQYGA EECVLQMGGV LCPRPGCGAG LLPEQGQKKV TCEGGNGLGC
     GFVFCRDCKE AYHEGECDSM FEASGATSQA YRVDQRAAEQ ARWEEASKET IKKTTKPCPR
     CNVPIEKNGG CMHMKCPQPQ CKLEWCWNCG CEWNRACMGD HWFDV
//
